Editas Medicine Announces Transition of Chief Financial Officer
December 21, 2018 09:00 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Dec. 21, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that its Chief Financial Officer, Andrew Hack, M.D.,...
Editas Medicine Names Cynthia Collins to Board of Directors
December 10, 2018 09:00 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it has appointed Cynthia Collins to its Board of...
Editas Medicine Announces Pre-Clinical Data Supporting Novel Approach for Treatment of Sickle Cell Disease and Beta-Thalassemia
December 02, 2018 19:35 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Dec. 02, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced results from experiments to demonstrate expanded CRISPR...
Editas Medicine Announces FDA Acceptance of IND Application for EDIT-101
November 30, 2018 07:30 ET
|
Editas Medicine, Inc.
EDIT-101 set to be the first in vivo CRISPR medicine administered to people anywhere in the world Earns $25 million milestone for IND acceptance from partner Allergan CAMBRIDGE, Mass., Nov. 30,...
Editas Medicine Announces Third Quarter 2018 Results and Update
November 07, 2018 16:01 ET
|
Editas Medicine, Inc.
Filed IND application for EDIT-101 with FDA in October Favorable Appeals Court ruling affirms strength of foundational intellectual property Oral presentation at ASH Annual Meeting to highlight...
Editas Medicine to Host Conference Call Discussing Third Quarter 2018 Corporate Update and Results
October 31, 2018 16:01 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Oct. 31, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on...
Editas Medicine Grows Scientific Leadership with Two New Appointments
October 01, 2018 09:00 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that Richard A. Morgan, Ph.D., a leading expert in gene...
Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Affirms Favorable U.S. Patent and Trademark Office Decision in CRISPR Interference
September 10, 2018 13:58 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, announced today that the U.S. Court of Appeals for the Federal Circuit...
Editas Medicine Announces Transition of Chief Medical Officer
August 27, 2018 16:01 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Aug. 27, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that its Chief Medical Officer, Gerald Cox, M.D., Ph.D.,...
Editas Medicine Announces the Completion of the Recombinant DNA Advisory Committee (RAC) Registration Process
August 16, 2018 16:01 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Aug. 16, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, announced today the National Institutes of Health (NIH) Recombinant DNA...